We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

41 hedge funds and large institutions have $144M invested in Protagonist Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 9

56% more capital invested

Capital invested by funds: $91.8M → $144M (+$51.8M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.08% less ownership

Funds ownership: 48.16% → 48.08% (-0.08%)

5% less funds holding

Funds holding: 43 → 41 (-2)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Holders
41
Holders Change
-2
Holders Change %
-4.65%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
17
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PC
Polar Capital
United Kingdom
+$692K
2
BCM
Bridgeway Capital Management
Texas
+$540K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$422K
4
FSA
Franklin Street Advisors
North Carolina
+$231K
5
First Manhattan
First Manhattan
New York
+$230K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$891K
2
SAM
Senzar Asset Management
New York
-$727K
3
GAMA
Graticule Asia Macro Advisors
New York
-$328K
4
Deutsche Bank
Deutsche Bank
Germany
-$320K
5
Renaissance Technologies
Renaissance Technologies
New York
-$294K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$44.8M +$96.3K +6,952 +0.3%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$36.3M – – –
PI
3
Pharmstandard International
Luxembourg
$17.4M – – –
CAM
4
Cormorant Asset Management
Massachusetts
$8.84M – – –
BlackRock
5
BlackRock
New York
$7.91M +$222K +16,059 +4%
Vanguard Group
6
Vanguard Group
Pennsylvania
$6.29M +$422K +30,460 +9%
SAM
7
Senzar Asset Management
New York
$3.9M -$727K -52,500 -19%
PC
8
Polar Capital
United Kingdom
$2.65M +$692K +50,000 +50%
Millennium Management
9
Millennium Management
New York
$2.43M -$891K -64,360 -32%
EAM
10
Eventide Asset Management
Massachusetts
$2.21M – – –
State Street
11
State Street
Massachusetts
$2.07M +$65.2K +4,709 +4%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.99M +$82.6K +5,962 +6%
Northern Trust
13
Northern Trust
Illinois
$1.73M -$16.8K -1,213 -1%
BCM
14
Bridgeway Capital Management
Texas
$689K +$540K +39,000 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$513K +$19.9K +1,435 +5%
PP
16
PDT Partners
New York
$458K +$118K +8,500 +49%
TCIM
17
TIAA CREF Investment Management
New York
$415K +$1.88K +136 +0.6%
Morgan Stanley
18
Morgan Stanley
New York
$341K +$151K +10,904 +130%
FSA
19
Franklin Street Advisors
North Carolina
$295K +$231K +16,700 New
First Manhattan
20
First Manhattan
New York
$293K +$230K +16,600 New
TA
21
Teachers Advisors
New York
$287K – – –
California State Teachers Retirement System (CalSTRS)
22
California State Teachers Retirement System (CalSTRS)
California
$272K -$16.6K -1,200 -7%
Charles Schwab
23
Charles Schwab
California
$234K – – –
RhumbLine Advisers
24
RhumbLine Advisers
Massachusetts
$178K +$277 +20 +0.2%
Wells Fargo
25
Wells Fargo
California
$169K +$50.1K +3,617 +61%
1
2

PTGX Hedge Fund Activity: Q3 2017 in Review

41 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2017, worth a combined $144M — up 56% from $91.8M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of PTGX and 5 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 17 added.

The largest buyer was Polar Capital, adding an estimated $692K. The largest seller was Millennium Management, cutting an estimated $891K.

  • 41 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2017, down from 43 in Q2 2017.
  • Funds reported $144M of Protagonist Therapeutics stock for Q3 2017, up 56% quarter-over-quarter.
  • 5 funds opened new Protagonist Therapeutics positions in Q3 2017 and 7 closed out, a net change of -2 holders.
  • The largest Protagonist Therapeutics buyer in Q3 2017 was Polar Capital, an estimated $692K added.
  • The largest Protagonist Therapeutics seller in Q3 2017 was Millennium Management, an estimated $891K sold.

Based on aggregated 13F filings for Q3 2017.